SCHEMBL16748528

SCHEMBL16748528

Cc1nc2ccc(F)cc2n1-c1nc(N)nc(Nc2ccc(OC(F)F)cc2)n1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BMI1 P35226 10/20 0.66
ROCK1 Q13464 1/20 0.39
DHFR P00374 2/20 0.38
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
GALR2 O43603 2/20 0.37
FFAR1 O14842 1/20 0.36
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
MEN1 O00255 1/20 0.35
BLM P54132 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16740746 0.91 BMI1 (0.67) BMI1ROCK1DHFRALDH1A1MAPT
SCHEMBL16748576 0.89 BMI1 (0.53) BMI1ROCK1ALDH1A1MAPTGALR2
SCHEMBL16740812 0.89 BMI1 (0.52) BMI1ROCK1DHFRALDH1A1MAPT
SCHEMBL16748450 0.89 BMI1 (0.52) BMI1DHFRALDH1A1MAPTL3MBTL1
SCHEMBL16748532 0.88 BMI1 (0.51) BMI1DHFRMAPTPIK3CDPIK3CA
SCHEMBL16748480 0.87 BMI1 (0.64) BMI1ROCK1PIK3CDPIK3CAPIK3CB
SCHEMBL16748578 0.87 BMI1 (0.52) BMI1ROCK1DHFRALDH1A1MAPT
SCHEMBL16740775 0.87 BMI1 (0.50) BMI1ROCK1DHFRALDH1A1MAPT
SCHEMBL16748445 0.87 BMI1 (0.50) BMI1DHFRALDH1A1MAPTL3MBTL1
SCHEMBL16748610 0.86 BMI1 (0.49) BMI1DHFRGALR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US claimed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US claimed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-9975878-B2 Substituted triazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2018-05-22 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-10-13 US disclosed
WO-2015076801-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297798-A1 SUBSTITUTED TRIAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B BMI1 1/4885ROCK1 2999/4885DHFR 4017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.